Masimo Corporation (MASI)
|Net Income (ttm)||229.23M|
|Trading Day||May 13|
|Day's Range||214.75 - 220.27|
|52-Week Range||203.81 - 284.86|
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that Masimo O3® Regional Oximetry may aid in monitoring septic shock patients and may have value as a predictor of mortality.
Here are the stocks seeing the most insider buying this week
Brian Sullivan's weekly segment on Worldwide Exchange brings you the top five stocks seeing the most insider buying action this week.
Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced the findings of the first study to evaluate the utility of PVi® on patients treated with nasal high-flow therapy.
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Masimo (MASI) delivered earnings and revenue surprises of 2.27% and 0.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Masimo (NASDAQ:MASI) remain flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 7.22% year over year to $0.90, which beat the est...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the first quarter of 2021, ended April 3, 2021. First Quarter 2021 Results: Product revenue increased 10....
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) has changed the date for the release of its first quarter 2021 financial results to Monday, April 26, 2021 due to executive scheduling changes. The...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release first quarter 2021 financial results for the period ended April 3, 2021, after the market closes on Tuesday, April 27, 2021. The confe...
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
Masimo Announces FDA Clearance of Radius PCG™ for the Root® Patient Monitoring and Connectivity Platform
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Radius PCG™, a portable mainstream capnograph that connects wirelessly to the Root® Patient Monitoring Hub, has received FDA clearance.
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the 20th Annual Needham Healthcare Conference on Monday, April 12, 2021 at 3:45 ...
Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study investigating the impact of rescue therapies on the brains of patients with severe COVID-19 used Masimo O3® Regional Oximetry.
Study Investigates the Impact of Automating Respiration Rate Measurement Using Masimo Rad-G™ with RRp®
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study evaluated the accuracy of Masimo RRp® by comparing it to manual respiration rate counting on hospitalized, malnourished children.
Masimo (MASI) reported earnings 30 days ago. What's next for the stock?
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Us...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new CCHD screening study with Masimo SET® pulse oximetry recommended the implementation of pulse oximetry screening for all newborns in Sri Lanka.
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheo...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found the Masimo EMMA® Capnograph useful in the assessment of respiratory condition in children with tracheostomy.
According to the All-in-One Screener, a Premium feature of GuruFocus, four companies that have high profitability, business predictability and free cash flow growth are Autohome Inc. (NYSE:ATHM), Masimo...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo provides a variety of innovative monitoring solutions designed to improve maternal and newborn safety, including SET® pulse oximetry.
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo Rad-G™ with Temperature, a rugged handheld device with SET® pulse oximetry, respiration rate, and temperature measurement, received CE marking.
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, M...
Shares of Masimo (NASDAQ:MASI) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 7.69% year over year to $0.98, which beat the estimate ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended January 2, 2021. Fourth Quarter 2020 Results: Total revenue for th...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo softFlow®, innovative high-flow nasal cannula therapy, is now available in the U.S. for spontaneously breathing adult patients.
Masimo Corporation (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.
Masimo to Report Fourth Quarter and Full Year 2020 Financial Results after Market Close on Tuesday, February 23
IRVINE, Calif.--(BUSINESS WIRE)--As previously announced on January 13, Masimo (NASDAQ: MASI) will release fourth quarter and full year 2020 financial results for the period ended January 2, 2021, after...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo SafetyNet-OPEN™, a web and mobile app solution that helps organizations stay open safely during COVID-19 and beyond, has full market release.
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the BTIG MedTech and Digital Health Conference on Thursday, February 18, 2021 at...
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo has successfully completed the acquisition of LiDCO, a leading provider of advanced hemodynamic monitoring systems.
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo announced iSirona™, a compact, versatile, connectivity hub that routes data from medical devices to the Masimo Hospital Automation™ platform.
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
The booming digital health space has been witnessing significant M&A activities amid the pandemic.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 2, 2021 and provided estimates for...
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
IRVINE, Calif.--(BUSINESS WIRE)--Masimo is helping Renown Health address the COVID-19 surge, in part through use of Masimo SafetyNet™, a remote patient management solution.
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress Postoperative Hyperoxia in Patients Undergoing Br...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study used Masimo ORi™, Oxygen Reserve Index, to help limit the extent of postoperative hyperoxia.
New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blo...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--In a study of pediatric patients, Masimo SpHb® was associated with improved outcomes, including reduced postoperative transfusion and ICU stays.
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion ind... [Read more...]
Medical Instruments & Supplies
|IPO Date |
Aug 8, 2007
|Stock Exchange |
|Ticker Symbol |
In 2020, Masimo's revenue was $1.14 billion, an increase of 21.96% compared to the previous year's $937.84 million. Earnings were $240.30 million, an increase of 22.47%.
According to 9 analysts, the average rating for Masimo stock is "Buy." The 12-month stock price forecast is 295.67, which is an increase of 34.94% from the latest price.